---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-038101"
form_type: "8-K"
ticker: "SGMT"
cik: "0001400118"
company_name: "Sagimet Biosciences Inc."
filed_at: "2024-03-25T23:59:59+00:00"
generated_at: "2026-06-04T08:24:25.476949+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sagimet FY2023 net loss $27.9M; denifanstat Phase 2b hits endpoints; board adds Walbert, Hoelscher

## Summary
- Net loss $27.9M for FY2023 vs $30.5M in 2022; revenue $2.0M from milestone payment.
- Cash, equivalents and securities $94.9M at Dec 31, 2023; Jan 2024 offering added $104.7M net.
- Denifanstat Phase 2b FASCINATE-2 met primary endpoints: MASH resolution 36% vs 13% (p=0.0022); fibrosis improvement 41% vs 18% (p=0.005).
- Board expanded from 7 to 9 directors; Tim Walbert (ex-Horizon CEO) and Paul Hoelscher (ex-Horizon CFO) appointed eff. April 1, 2024.
- Directors Richard Rodgers and Jinzi Wu will not stand for re-election at June 2024 annual meeting.

## SEC filing metadata
- accession: 0001104659-24-038101
- form_type: 8-K
- ticker: SGMT
- cik: 0001400118
- company_name: Sagimet Biosciences Inc.
- filed_at: 2024-03-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1400118/000110465924038101/0001104659-24-038101-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1400118/000110465924038101/tm249600d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-038101
- JSON: https://secwatch.observer/filing/0001104659-24-038101.json
- Plain text: https://secwatch.observer/filing/0001104659-24-038101.txt

## Key facts
- Earnings Releases
  Sagimet Biosciences Inc. reported fourth quarter and year ended December 31, 2023 results: revenue $2.0 million.
  - Period: fourth quarter and year ended December 31, 2023
  - Revenue: $2.0 million
  - Result: reported results
  source text: offering, are expected to fund operations for at least the next 12 months based on management’s current operating plan. · Revenues for the year ended December 31, 2023 were $2.0 million compared to no revenues for fiscal 2022. The increase was due to a $2.0 million milestone payment that was recognized in July 2023. · Research and development (R&D) expense for
  evidence_url: https://www.sec.gov/Archives/edgar/data/1400118/000110465924038101/0001104659-24-038101-index.htm
- Executive change
  Paul Hoelscher was appointed as Director at Sagimet Biosciences Inc..
  - Action: appointed
  - Role: Director
  source text: the appointment of each of Tim Walbert and Paul Hoelscher to serve as directors of the Board, in each case effective as of April 1, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1400118/000110465924038101/0001104659-24-038101-index.htm
- Executive change
  Tim Walbert was appointed as Director at Sagimet Biosciences Inc..
  - Action: appointed
  - Role: Director
  source text: the appointment of each of Tim Walbert and Paul Hoelscher to serve as directors of the Board, in each case effective as of April 1, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1400118/000110465924038101/0001104659-24-038101-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.